WHO guideline on country pharmaceutical pricing policies

WHO guideline on country pharmaceutical pricing policies PDF

Author:

Publisher: World Health Organization

Published: 2020-09-29

Total Pages: 70

ISBN-13: 9240011870

DOWNLOAD EBOOK →

In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems' ability to provide population-wide access to essential medicines. Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products. This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.

Countering the Problem of Falsified and Substandard Drugs

Countering the Problem of Falsified and Substandard Drugs PDF

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2013-06-20

Total Pages: 377

ISBN-13: 0309269393

DOWNLOAD EBOOK →

The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.

Making Medicines Affordable

Making Medicines Affordable PDF

Author: National Academies of Sciences, Engineering, and Medicine

Publisher: National Academies Press

Published: 2018-03-01

Total Pages: 235

ISBN-13: 0309468086

DOWNLOAD EBOOK →

Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.

Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy

Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy PDF

Author:

Publisher: Springer Nature

Published: 2023-10-14

Total Pages: 1358

ISBN-13: 3030644774

DOWNLOAD EBOOK →

This encyclopedia covers the definitions, concepts, methods, theories, and application of evidence-based pharmaceutical public health and health services research. It highlights why and how this field has a significant impact on healthcare. The work aims to synthesize baseline knowledge as well as the latest and cutting-edge research-based information. The encyclopedia collates information on public health, health services research, evidence-based pharmacy practice and its impacts on patients, decision-makers and consumers. This reference work discusses all aspects of policy and practice decisions on medicines use, access and pharmacy services by covering broad aspects related to pharmacy practice, public health and health services research. The aim is to develop high-quality content, which will be a must-read and be used as a reference source at all pharmacy and medical schools in the world. The health services research investigates the impact of social factors, organizational policies, financing systems, medical technologies and personal influence on access, quality and cost of healthcare concerning the quality of life of the patients. This reference work fundamentally promotes the evidence-based evaluation of healthcare services and thus will improve the better access and delivery of healthcare services. Also, pharmacy, medical and health services students and researchers need a broad understanding of pharmaceutical public health, evidence-based approaches to delivering care, changing professional and patient behavior and undertaking research in these areas. In general, there is a need to build research capacity and capability in the pharmacy profession. EDITOR-IN-CHIEF: Professor Zaheer-Ud-Din Babar, University of Huddersfield SECTION EDITORS: Filipa Alves da Costa, University of LisbonZubin Austin, University of TorontoDalia Dawood, National Institute for Health and Care Excellence Andy Gray, University of Kwa Zulu-NatalRachele Hendricks-Sturrup, Duke Margolis Center for Health PolicyJason Hsu, Taiwan Medical UniversityRabia Hussain, Universiti Sains MalaysiaChristine Y. Lu, Harvard Medical School and Harvard Pilgrim Health Care InstituteMohamed Izham Mohamed Ibrahim, Qatar UniversityPrasad Nishtala, University of BathDerek Charles Stewart, College of Pharmacy, Qatar University Fatima Suleman, University of Kwa Zulu-NatalZaheer-Ud-Din Babar, University of Huddersfield

A Practical Approach to Pharmaceutical Policy

A Practical Approach to Pharmaceutical Policy PDF

Author: Andreas Seiter

Publisher: World Bank Publications

Published: 2010-06-17

Total Pages: 238

ISBN-13: 9780821383872

DOWNLOAD EBOOK →

This book offers policy makers a hands-on approach, tested in the World Bank’s field work in many countries, for developing policies that improve access to safe, effective medicines in health systems of low- and middle-income economies.

Pain Management and the Opioid Epidemic

Pain Management and the Opioid Epidemic PDF

Author: National Academies of Sciences, Engineering, and Medicine

Publisher: National Academies Press

Published: 2017-09-28

Total Pages: 483

ISBN-13: 0309459575

DOWNLOAD EBOOK →

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

Promoting Access to Medical Technologies and Innovation - Intersections between Public Health, Intellectual Property and Trade

Promoting Access to Medical Technologies and Innovation - Intersections between Public Health, Intellectual Property and Trade PDF

Author: World Intellectual Property Organization

Publisher: WIPO

Published: 2013

Total Pages: 259

ISBN-13: 9280523082

DOWNLOAD EBOOK →

This study has emerged from an ongoing program of trilateral cooperation between WHO, WTO and WIPO. It responds to an increasing demand, particularly in developing countries, for strengthened capacity for informed policy-making in areas of intersection between health, trade and IP, focusing on access to and innovation of medicines and other medical technologies.